Media Library
icon
-
PDFlockPublications / ReportNovartis in Society Integrierter Geschäftsbericht 2022
The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders. This is the German version of the report.
-
PDFlockPublications / ReportNovartis in Society Integrated Report 2022
The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders.
-
PDFlockPublications / ReportNovartis Annual Report 2022
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements.
-
PDFlockPublications / ReportNovartis Annual Report 2021
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements.
-
PDFlockNovartis Social Business / ReportNovartis Access one-year report
The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.
-
PDFlockNovartis Access / ReportNovartis Access two-year report
Since 2015, Novartis Access has worked to deliver treatments for chronic diseases in lower-income countries. Read our two-year report for an in-depth look at results, learnings and challenges on the ground so far. It includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.
-
PDFlockCorporate Responsibility / ReportCorporate Responsibility Report 2017
As a leading healthcare company, we have a responsibility to help people get access to the treatments they need, no matter where they live. Our CR Performance Report gives you all the facts on the progress we are making. It is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.
-
PDFlockNovartis Social Business / ReportHealthy Family 10-year report
10 years ago we launched the Healthy Family program, Novartis first social business model, to improve health via education, affordable products and health services. This report provides information on how the program has evolved since then. It includes external perspectives and country updates, showcasing the learnings and progress we have made over the years.
-
PDFlockPublications / ReportNovartis Annual Report 2017
The Annual Report provides an overview of our strategy and reviews the performance of Novartis in 2017.
-
PDFlockPublications / ReportNovartis Annual Report 2018
Our Annual Report 2018 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results.
-
PDFlockCorporate Responsibility / ReportMalaria Futures for Africa
MalaFA (Malaria Futures for Africa) is an opinion research study commissioned by Novartis to capture the views of African malaria experts in 15 sub-Saharan African countries – from government, the research community and NGOs – on progress and remaining challenges toward the 2030 global malaria goals. Study co-chairs are Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust programme, Kenya and University of Oxford, United Kingdom.
-
PDFlockPublications / ReportNovartis in Society Report 2018
Transparent reporting has been a central part of our CR commitment for many years, and we continue to make progress in this area. Our Novartis in Society Report (formerly the Corporate Responsibility Report) is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.